TERT promoter mutations were detected only in gliomas and not in other types of brain tumor (Fig. 1A), indicating that the identified mutations could serve as glioma-specific biomarkers to predicting tumor occurrence or recurrence. This evidence concerns the gene TERT and central nervous system cancer.